Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
2024年3月4日 - 10:00PM
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company
developing innovative, full-length multispecific antibodies
(Biclonics® and Triclonics®), today announced that Bill Lundberg,
M.D., President, Chief Executive Officer of Merus, will participate
in in a fireside chat at the Leerink Partners Global Biopharma
Conference on Monday, March 11, 2024 at 12:00 p.m. ET.
The webcast of the presentation will be contemporaneously
available on the Investors page of the Company's website. The
archived presentation will also be available there for a limited
time after the event.
About MerusMerus is a
clinical-stage oncology company developing innovative full-length
human bispecific and trispecific antibody therapeutics, referred to
as Multiclonics®. Multiclonics® are manufactured using industry
standard processes and have been observed in preclinical and
clinical studies to have several of the same features of
conventional human monoclonal antibodies, such as long half-life
and low immunogenicity. For additional information, please visit
Merus’ website, X and LinkedIn.
Multiclonics®, Biclonics® and Triclonics® are registered
trademarks of Merus N.V.
Investor and Media Inquiries:
Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
s.spear@merus.nl
Kathleen Farren
Merus N.V.
IR/Corp Comms
617-230-4165
k.farren@merus.nl
Merus NV (NASDAQ:MRUS)
過去 株価チャート
から 5 2024 まで 6 2024
Merus NV (NASDAQ:MRUS)
過去 株価チャート
から 6 2023 まで 6 2024